Biotie Therapies - Changes board/management/auditors

Change in the Board of Directors

Biotie Therapies Corp.          Stock Exchange Release    2 May 2012 at 10.45
a.m.

Change in the Board of Directors

Dr. James S. Shannon has notified the company that he will resign from the Board
of Directors of Biotie, effective immediately. Dr. Shannon has been appointed
Corporate Chief Medical Officer with GlaxoSmithKline in London as of May
1st 2012 and will resign from all external Board positions.

Peter Fellner, William M. Burns, Merja Karhapää, Bernd Kastler, Ismail Kola, and
Guido Magni will continue as members of the Board of Directors of Biotie, with
Peter Fellner as Chairman and William M. Burns as the deputy chairman. The
consequences of Dr. Shannon's resignation from the Board to the composition of
the Company's Audit and Nomination and Remuneration committees will be assessed
separately."On behalf of the Board, I would like to thank James for the strong contribution
he has made since he was appointed in 2010 and wish him well for the future,"
said Peter Fellner, Chairman of the Board of Directors of Biotie.

Turku, 2 May 2012

Biotie Therapies Corp.



Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.

The company has a strong and balanced development portfolio with several
innovative small molecule and biological drug candidates at different stages of
clinical development. Biotie's products address diseases with high unmet medical
need and significant market potential.

Partnerships with top-tier pharmaceutical partners are in place for several
programs as well as a strategic collaboration with UCB Pharma S.A. The Marketing
Authorization Application for Biotie's most advanced product, Selincro(TM)
(nalmefene) for alcohol dependence was filed in the EU by our partner H.
Lundbeck A/S and was accepted for review by the European Medicines Agency in
December 2011.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.


[HUG#1607862]